탈장 치료 시장 : 제품 유형별, 수술 방법별, 탈장 유형별, 최종 사용자별 - 시장 예측(2026-2032년)

The Hernia Repair Market was valued at USD 5.04 billion in 2025 and is projected to grow to USD 5.31 billion in 2026, with a CAGR of 5.45%, reaching USD 7.31 billion by 2032.

A forward-looking introduction synthesizing surgical evolution, material innovation, and care model shifts that are reshaping clinical practice and supplier strategies

Hernia repair continues to evolve at the intersection of surgical innovation, material science, and shifting care delivery models. This executive summary synthesizes contemporary drivers shaping the field, highlights inflection points for suppliers and providers, and frames high-impact opportunities for stakeholders across the care continuum.

Clinical practice now emphasizes outcomes beyond simple recurrence metrics, with tissue integration, infection resistance, and patient-reported recovery experience gaining prominence. Concurrently, device manufacturers are refining material formulations and scaffold architectures to address both acute and chronic repair needs, while health systems press for procedures that reduce length of stay and readmission risk. As minimally invasive approaches expand, perioperative pathways and device compatibility with laparoscopic techniques are increasingly decisive factors for procurement and adoption.

Regulatory scrutiny and payer engagement continue to influence product development strategies and evidence generation priorities, prompting manufacturers to integrate real-world data and comparative-effectiveness endpoints into their clinical programs. Moreover, cross-disciplinary collaboration among surgeons, materials scientists, and regulatory experts is accelerating translational steps from bench innovations to bedside adoption. The following sections unpack these dynamics and offer pragmatic insights for leaders navigating this complex landscape.

An analytical review of converging technological, procedural, and regulatory shifts that are redefining product requirements and clinical adoption pathways in hernia repair

The hernia repair landscape is undergoing transformative shifts driven by converging technological advances, policy changes, and evolving clinical expectations. Advances in biomaterials and synthetic scaffolds are enabling next-generation implants that emphasize biocompatibility, tailored degradation profiles, and surface engineering to mitigate infection and adhesion risks. These material innovations are not isolated; they interact with procedural trends-particularly the broader adoption of minimally invasive techniques-to reshape product requirements and performance benchmarks.

Parallel to technological progress, healthcare delivery models are moving care episodes from inpatient wards to ambulatory settings wherever clinically appropriate, prompting product design considerations for ease of use, sterility assurance, and the facilitation of shorter recovery pathways. Regulatory pathways are also adapting, with authorities increasingly requiring robust clinical endpoints and post-market surveillance strategies, which in turn drive manufacturers to invest in longer-term outcome studies and real-world evidence systems.

Collectively, these factors create a higher bar for clinical differentiation while opening opportunities for companies that align device features with workflow efficiencies and evidence generation. Payers and hospitals are simultaneously rationalizing device formularies and care bundles, making collaborative value demonstration and interoperability with standard surgical platforms decisive for market penetration.

A comprehensive assessment of how anticipated 2025 tariff shifts will affect procurement, supply chain resilience, and strategic sourcing for hernia repair stakeholders

Anticipated tariff adjustments in the United States in 2025 introduce a layer of complexity to procurement strategies and global supply chain planning for hernia repair devices. Tariff dynamics can influence cost structures for imported materials and finished implants, and they therefore affect sourcing decisions, inventory strategies, and commercial pricing. Organizations that manage cross-border supplier relationships must reassess contractual terms, logistics routing, and duty mitigation strategies to preserve competitiveness.

In response to tariff-driven cost pressures, manufacturers and healthcare systems may re-evaluate localization of production, increase emphasis on regional supplier diversification, and refine total landed cost models rather than relying on unit price alone. Such adjustments can accelerate trends toward nearshoring or strategic stockpiling of critical components, while also prompting more rigorous supplier performance analytics to identify resilience gaps.

Clinically, tariff-related cost shifts could influence hospital procurement committees' device selection criteria and negotiations with vendors, particularly where alternative materials or domestic suppliers offer comparable clinical performance. Importantly, the cumulative impact of tariffs is not limited to price alone; it also affects timelines for technology transfer, regulatory submissions tied to manufacturing changes, and long-term partnerships. Organizations that proactively model tariff scenarios and integrate them into commercial and operational planning will mitigate disruption and preserve strategic flexibility.

A deep segmentation-driven perspective linking material classes, procedural subtypes, anatomical indications, and care settings to inform tailored clinical and commercial strategies

Segmentation insight is essential to understand how distinct product characteristics, procedural approaches, hernia types, and care settings intersect to shape clinical decision-making and commercial strategy. When considering product type, analyses must differentiate between Biological Mesh and Synthetic Mesh; the Biological Mesh category further divides into animal-derived and human-derived constructs, while Synthetic Mesh encompasses polyester, polypropylene, and polytetrafluoroethylene variants, each presenting unique handling, integration, and infection-resistance profiles. These material distinctions influence surgeon preference, sterilization protocols, and postoperative management expectations.

Procedure type segmentation distinguishes laparoscopic from open approaches, with laparoscopic techniques further classified into total extraperitoneal and transabdominal preperitoneal methods. Device design and delivery systems need to align with these procedural subtypes to ensure compatibility with trocar sizes, fixation strategies, and visualization workflows. Meanwhile, hernia type segmentation across hiatal, incisional, inguinal, umbilical, and ventral presentations underscores the need for tailored implant geometries, fixation options, and perioperative care pathways that reflect anatomical and biomechanical variations.

End user segmentation divides the landscape among ambulatory surgical centers, clinics, and hospitals, each with different procurement cycles, case mixes, and facility resources. Ambulatory centers prioritize fast turnover and simplified supply chains, clinics may focus on outpatient continuity of care, and hospitals must balance complex, high-acuity cases with broader procurement governance. Integrating these segmentation lenses enables targeted product positioning, evidence generation plans, and commercialization tactics that resonate with the specific operational realities of each buyer type.

A nuanced regional analysis that aligns divergent clinical practices, regulatory regimes, and supply chain realities across the Americas, EMEA, and Asia-Pacific to guide market entry and scale plans

Regional dynamics exert substantial influence over clinical practice patterns, regulatory expectations, and supply chain architectures, creating distinct strategic considerations across geographies. In the Americas, healthcare delivery emphasizes both large academic centers and an expanding network of ambulatory surgical settings, which together create demand for devices that balance advanced clinical performance with operational efficiency; reimbursement models and public-private payer mixes also shape procurement priorities and evidence requirements.

Across Europe, the Middle East & Africa, regulatory diversity and heterogeneous payer landscapes necessitate flexible market entry strategies and adaptable clinical data packages. Device acceptance here often hinges on regional clinical opinion leaders and country-specific health technology assessment processes, making phased rollouts and local investigator-led studies valuable. In the Asia-Pacific region, rapid infrastructure development, increasing access to minimally invasive surgery, and variable domestic manufacturing capacity create opportunities for both innovative importers and locally based producers; procurement decisions frequently reflect a mix of cost sensitivity and a rising emphasis on clinical outcomes.

Taken together, these regional differences require manufacturers to tailor regulatory strategies, distribution partnerships, and clinical engagement plans. Strategic localization of evidence generation, targeted training programs for surgeons across differing procedural norms, and supply chain arrangements that reflect regional logistics realities will be decisive for commercial success.

A strategic synthesis of competitive forces, innovation focus areas, and partnership models that are redefining differentiation and value capture in hernia repair markets

Competitive dynamics in the hernia repair space reflect a balance between established surgical supply leaders and emerging innovators in biomaterials and fixation technologies. Leading firms continue to invest in iterative improvements to polymer and biologic scaffolds, enhanced delivery systems for minimally invasive procedures, and evidence generation that supports value-based procurement conversations. Meanwhile, smaller specialized players focus on disruptive material chemistries, surface modifications, and adjunct technologies such as antimicrobial coatings and absorbable fixation devices.

Partnerships between device manufacturers and clinical centers of excellence have become instrumental in accelerating adoption by demonstrating procedural efficiencies and patient-centric outcomes. Strategic collaborations with contract manufacturers and regional distributors further enable scale while managing cost structures. Intellectual property around material science and proprietary manufacturing processes remains a critical differentiator, as does the ability to integrate post-market surveillance and registries that document long-term performance.

As adoption criteria shift toward holistic value, companies that can present robust clinical evidence, streamlined logistics, and compelling surgeon training programs will maintain competitive advantage. Organizations should also monitor emerging entrants that leverage digital health adjuncts, such as surgical planning tools or analytics platforms, which can complement device offerings and create integrated value propositions for hospital systems and ambulatory centers alike.

Actionable, implementation-focused recommendations for leaders to align R&D, supply chain, and commercial models with clinical outcomes and payer expectations in hernia repair

Industry leaders can take decisive actions to convert emerging trends into sustainable advantages by aligning R&D, commercial, and operational priorities with clinical and payer demands. First, prioritize investment in materials and delivery systems that demonstrably improve integration, reduce infection risk, and simplify implantation for both open and laparoscopic techniques, supported by pragmatic clinical endpoints and real-world evidence collection initiatives. Second, establish cross-functional evidence-generation roadmaps that incorporate surgeon-led registries and post-market surveillance to satisfy regulators and purchasers while shortening the feedback loop for iterative product improvements.

Operationally, strengthen supply chain resilience by diversifying sources for critical inputs and exploring regional manufacturing options to mitigate tariff and logistics exposure. Cultivate robust training and proctoring programs tailored to ambulatory surgical center workflows and hospital operating suites, thereby reducing variation in clinical outcomes and accelerating institutional adoption. Finally, pursue value-driven commercial models that align pricing and reimbursement approaches with demonstrable clinical benefits and total episode-of-care efficiencies.

By executing these strategic moves, leaders will be positioned to navigate regulatory complexity, meet evolving clinical expectations, and secure durable partnerships with providers and payers. These recommendations emphasize practical implementation pathways that balance near-term operational resilience with long-term innovation-led differentiation.

A transparent, mixed-methods research design combining clinician insights, regulatory and clinical literature review, and supply chain scenario analysis to validate conclusions and recommendations

The research underpinning this executive synthesis integrates a structured combination of primary and secondary information-gathering methods designed to ensure analytical rigor and practical relevance. Primary inputs included structured interviews with clinical specialists across general and minimally invasive surgery, procurement leaders from ambulatory, clinic, and hospital settings, and subject-matter experts in biomaterials and regulatory affairs. These qualitative discussions informed hypothesis generation and prioritized areas for deeper analysis.

Secondary research encompassed peer-reviewed clinical literature, regulatory filings, device labeling information, and publicly available health policy documents to frame clinical performance attributes and regulatory trends. Comparative device characteristics and procedural technique literature were triangulated with real-world practice insights to validate clinical relevance. Supply chain and tariff scenario analysis relied on trade data, logistics expert commentary, and scenario planning methodologies to assess operational implications under different assumptions.

Analytical approaches combined thematic synthesis from qualitative interviews with cross-sectional comparative analyses of device attributes and care pathways. Quality assurance steps included cross-validation of key findings with multiple clinical sources and a review by external advisors to ensure objectivity. This mixed-methods approach supports actionable conclusions while maintaining methodological transparency and traceability.

A conclusive synthesis emphasizing the imperative to combine clinical evidence, operational resilience, and tailored commercialization to realize improved outcomes and sustainable value

In summary, the hernia repair field is at an inflection point driven by material innovation, procedural evolution toward minimally invasive care, and shifting procurement dynamics influenced by regional considerations and trade policy changes. Stakeholders who integrate rigorous clinical evidence generation with pragmatic supply chain and commercialization strategies will secure strategic advantages in a competitive landscape where clinical differentiation and operational efficiency matter equally.

Decision-makers should view device selection and partnership choices through a multidimensional lens that accounts for product attributes, procedural compatibility, patient outcomes, and care setting constraints. Regulatory and reimbursement dynamics necessitate an emphasis on demonstrable value, while tariff and supply chain considerations underscore the importance of operational resilience. Ultimately, organizations that align clinical innovation with real-world implementation plans-supported by targeted evidence and strong clinical partnerships-will be best positioned to deliver improved patient outcomes and sustainable commercial performance.

This report offers a foundation for such alignment and serves as a practical reference for clinical, commercial, and operational leaders seeking to translate insight into effective action within the evolving hernia repair landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hernia Repair Market, by Product Type

• 8.1. Biological Mesh
  • 8.1.1. Animal
  • 8.1.2. Human
• 8.2. Synthetic Mesh
  • 8.2.1. Polyester
  • 8.2.2. Polypropylene
  • 8.2.3. Polytetrafluoroethylene

9. Hernia Repair Market, by Procedure Type

• 9.1. Laparoscopic
  • 9.1.1. Total Extraperitoneal
  • 9.1.2. Transabdominal Preperitoneal
• 9.2. Open

10. Hernia Repair Market, by Hernia Type

• 10.1. Hiatal
• 10.2. Incisional
• 10.3. Inguinal
• 10.4. Umbilical
• 10.5. Ventral

11. Hernia Repair Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Clinics
• 11.3. Hospitals

12. Hernia Repair Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Hernia Repair Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Hernia Repair Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Hernia Repair Market

16. China Hernia Repair Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. AbbVie Inc.
• 17.6. Aran Biomedical by Integer Holdings Corporation
• 17.7. B. Braun SE
• 17.8. Baxter International Inc.
• 17.9. Becton, Dickinson and Company
• 17.10. Betatech Medical
• 17.11. BioCer Entwicklungs-GmbH
• 17.12. Boston Scientific Corporation
• 17.13. Coloplast A/S
• 17.14. CooperSurgical, Inc.
• 17.15. Cousin Surgery
• 17.16. Deep Blue Medical Advances, Inc.
• 17.17. Dolphin Sutures
• 17.18. Getinge AB
• 17.19. HERNIAMESH S.r.l.
• 17.20. Hwainmedi Co., Ltd.
• 17.21. Insightra Medical Inc.
• 17.22. Integra LifeSciences Holdings Corporation
• 17.23. Intuitive Surgical, Inc.
• 17.24. Johnson & Johnson Services, Inc.
• 17.25. KATSAN Katgut Sanayi ve Tic. A.S.
• 17.26. Medtronic PLC
• 17.27. Meril Life Sciences Pvt. Ltd.
• 17.28. Momentis Surgical Ltd.
• 17.29. Novus Scientific AB
• 17.30. Olympus Corporation
• 17.31. Secant Group, LLC
• 17.32. Surgimatix, Inc.
• 17.33. TELA Bio, Inc.
• 17.34. W. L. Gore & Associates, Inc.
• 17.35. Zimmer Biomet Holdings, Inc.